Cardiovascular Risk of Celecoxib in 6 Randomized Placebo - Controlled Trials
نویسندگان
چکیده
Scott D. Solomon, MD; Janet Wittes, PhD; Peter V. Finn, MD; Robert Fowler, MS; Jaye Viner, MD, MPH; Monica M. Bertagnolli, MD; Nadir Arber, MD; Bernard Levin, MD; Curtis L. Meinert, PhD; Barbara Martin, PhD; Joseph L. Pater, MD, MSc; Paul E. Goss, MD, PhD; Peter Lance, MD; Stefanie Obara, BS; Emily Y. Chew, MD; Jonghyeon Kim, PhD; Gretchen Arndt, MHSA; Ernest Hawk, MD, MPH; for the Cross Trial Safety Assessment Group
منابع مشابه
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
BACKGROUND Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with ce...
متن کاملCardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
AIM The present meta-analysis attempted to assess whether an unfavourable cardiovascular risk profile could be identified in the case of two COX2 selective inhibitors (COXIBs), namely celecoxib and etoricoxib. Based on the data from the literature, our meta-analysis aimed to assess the probability of major cardiovascular events reported with the use of celecoxib or etoricoxib and compare this w...
متن کاملPilot randomized phase II study of celecoxib in oral premalignant lesions.
PURPOSE Cyclooxygenase-2 (COX-2)-specific inhibition suppresses carcinogenesis in preclinical models and is a promising strategy for preventing oral cancer. In this pilot randomized phase II study, we evaluated the efficacy and safety of the COX-2 inhibitor celecoxib in patients with oral premalignant lesions (OPL). EXPERIMENTAL DESIGN Patients were randomly assigned to placebo (n=18), celeco...
متن کاملThe Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial
The Effect of Curcumin on Some of Traditional and Non-Traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial Abstract Numerous interventional studies in clinical and preclinical setting stated that intake of curcumin may provide protection against cardiovascular disease. The aim of this trial was investigation of curcumin efficiency on some cardiovas...
متن کاملA Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Safety of Dapagliflozin in Type 1 Diabetes Patients
Background and Purpose: The dapagliflozin’s safety profile in insulin-treated adult type-1 diabetes mellites (T1DM) patients remains poorly explored. Therefore, this systematic review and meta-analysis compared the risk of all-cause side effects, study discontinuation of participants due to side effects, urinary tract infection (UTI), diabetic ketoacidosis, and hypoglycemia between dapagliflozi...
متن کاملCardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
OBJECTIVES The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to evaluate the conventional NSAID naproxen sodium and the selective COX-2 inhibitor celecoxib for primary prevention of Alzheimer's dementia (AD). On 17 December 2004, after the Adenoma Prevention with Celecoxib (APC) trial reported increased cardiovascular risks with celecoxib, the ADAPT Steering Commit...
متن کامل